hsa-mir-4687: Hsa-mir-4687, along with other miRNAs such as hsa-mir-216b, hsa-mir-363, hsa-mir-940, and hsa-mir-1301, was found to be highly expressed in endometrial cancer (EC) tissues compared to normal tissues [PMC8806668]. However, the expression of hsa-mir-4687 in tumor tissues was contrary to the bioinformatics analysis [PMC8806668]. In addition to hsa-mir-4687, other miRNAs such as hsa-mir-3614 and hsa-mir-3170 were also highly expressed in tumor tissues compared to normal tissues [PMC8806668]. Conversely, five miRNAs including hsa-mir-3614 and hsa-mir-4687 were found to be low-expressed in EC tissues [PMC9318842]. These miRNAs were associated with poor prognosis and lower survival rate in endometrial cancer [PMC9318842]. Hsa-miR-4687 was also identified as playing a role in lung adenocarcinoma and its expression was found to be normal in the circulatory system of cancer patients [PMC9318842]. The super channel of the hsa-miR-4687 gene includes class I MHC-mediated antigen processing and presentation as well as antigen activated B-cell receptor (BCR) pathways that contribute to maintaining homeostasis [PMC9318842]. Finally, a prediction model for EC included 12 miRNA variables including HSA-MIR 138–2, HSA-MIR 548f–1, HSA-MIR 934–1/934–2/934–3/934–4/934–5/934–6/934–7/934–8 (HSA-MIR 934), HSA-MIR 940, HSA-MIR 4758, HSA-MIR 146a, HSA-MIR 3170, HSA-MIR 3614, HSA-MIR 3616, HSA-MIR 4687, HSA-MIR 876 and hsa-mir-1269a [PMC9318842]. The low expression of hsa-mir-4687 was found to be associated with decreased immune response reactivity and the formation of the tumor microenvironment [PMC9318842].